Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that v::RET status confers therapeutic sensitivity to Selpercatinib in patients with Non-Small Cell Lung Cancer.
The European Medicines Agency (EMA) has conditionally authorized selpercatinib for the treatment of adult patients with advanced RET fusion-positive non-small cell lung cancer not previously treated with a RET inhibitor.
This statement is based on a regulatory approval from the European Medicines Agency:
Retsevmo as monotherapy is indicated for the treatment of adults with advanced RET fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor.